This study uniquely contributes to the current literature by being the first to evaluate and report significant reductions in SCORE2-DM cardiovascular risk scores associated with SGLT2 inhibitor therapy over a six-month period in patients with Type 2 diabetes mellitus. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.